TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7036710

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 57
Study: 31190442

Group type: EXPERIMENTAL
Intervention: Chemotherapy for pediatric acute myeloid leukemia (AML)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 348
Study: 30021671

Group type: EXPERIMENTAL
Intervention: Carotenoid complex (50 mg) + 50 mg oil palm-derived vitamin E + unrestricted palm-derived water-soluble antioxidants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 mg d-α-tocopheryl acetate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 mg oil palm-derived vitamin E
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unrestricted water-soluble antioxidants
Number of subjects: 40
Study: 26771270

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Psoas Compartment Block (PCB)
Number of subjects: 150
Study: 24695896

Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (20 μg/d)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Vitamin D₃
Number of subjects: 125
Study: 23304689

Group type: EXPERIMENTAL
Intervention: Cemented implant-supported single crown
Number of subjects: 18

Group type: COMPARATOR
Intervention: Screw-retained implant-supported single crown
Number of subjects: 18
Study: 19941696

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 50 mg eq.
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg eq.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (both doses)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 197
Study: 17055609

Group type: EXPERIMENTAL
Intervention: Chewing spearmint gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no chewing gum)
Number of subjects: 0
Study: 15958785

Group type: EXPERIMENTAL
Intervention: Injury prevention program based on physician-community partnerships and private foundation support
Number of subjects: 0
Study: 12139269

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg plus codeine 30 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Paracetamol 1000 mg alone
Number of subjects: 82
Study: 9865013

Group type: EXPERIMENTAL
Intervention: Therapeutic plasmapheresis (TP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Therapeutic plasmapheresis (TP) + alpha-tocopherol treatment (AT)
Number of subjects: 46
Study: 8560531

Group type: EXPERIMENTAL
Intervention: Artesunate (4 mg/kg/d for 3 d) + mefloquine (25 mg/kg)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Artemether (4 mg/kg/d for 3 d) + mefloquine (25 mg/kg)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Mefloquine alone (25 mg/kg)
Number of subjects: 540
Study: 1696846

Group type: EXPERIMENTAL
Intervention: VAB-6 (cyclophosphamide + vinblastine + bleomycin + dactinomycin + cisplatin; 81 patients)
Number of subjects: 162

Group type: COMPARATOR
Intervention: etoposide + cisplatin (EP; 81 patients)
Number of subjects: 162
Study: 350262

Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg three times daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31963239

Group type: EXPERIMENTAL
Intervention: Fermented dairy (yogurt and acidified milk)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-fermented dairy (milk and cheese)
Number of subjects: 23
Study: 31793482

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 110

Group type: COMPARATOR
Intervention: DPNB
Number of subjects: 110
Study: 28722100

Group type: EXPERIMENTAL
Intervention: Integrative-psychotherapeutic treatment program consisting of 16 weekly sessions including vestibular rehabilitation training and modules for anxiety, panic disorder, depression, and somatisation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot trial
Number of subjects: 0
Study: 26638592

Group type: EXPERIMENTAL
Intervention: Direct field block with 40 ml of 0.125% bupivacaine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Spinal block with intrathecal morphine (Control)
Number of subjects: 56
Study: 23941601

Group type: EXPERIMENTAL
Intervention: Poliglecaprone‐25
Number of subjects: 140

Group type: COMPARATOR
Intervention: Polyglactin‐910
Number of subjects: 140
Study: 21518010

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 19147732

Group type: EXPERIMENTAL
Intervention: 10 mg/day atorvastatin
Number of subjects: 2350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2350
Study: 17530496

Group type: EXPERIMENTAL
Intervention: Anxious mood condition (anxiety-related coping motivated drinkers)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Anxious mood condition (enhancement-motivated drinkers)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Positive mood condition (enhancement-motivated participants)
Number of subjects: 47
Study: 15631287

Group type: EXPERIMENTAL
Intervention: OVAT screening tool
Number of subjects: 306

Group type: COMPARATOR
Intervention: ISA (Index of Spouse Abuse)
Number of subjects: 306
Study: 11005043

Group type: EXPERIMENTAL
Intervention: ECT with high dosage (2.5 times seizure threshold)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ECT with bilateral electrode placement
Number of subjects: 62

Group type: COMPARATOR
Intervention: ECT with right unilateral electrode placement
Number of subjects: 62

Group type: COMPARATOR
Intervention: ECT with stimulus dosage just above seizure threshold
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clinical outcome following ECT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patient age, initial seizure threshold, and baseline depression severity
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Postictal bioelectric suppression
Number of subjects: 62
Study: 9483233

Group type: EXPERIMENTAL
Intervention: Intravenous heparin (5000 unit bolus followed by 1000 units per hour, adjusted by nomogram)
Number of subjects: 108
Study: 8368420

Group type: EXPERIMENTAL
Intervention: High-top shoes
Number of subjects: 622

Group type: COMPARATOR
Intervention: Low-top shoes
Number of subjects: 622

Group type: COMPARATOR
Intervention: High-top shoes with inflatable air chambers
Number of subjects: 622
Study: 3792362

Group type: EXPERIMENTAL
Intervention: 111In-platelet scintigraphy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two-dimensional echocardiography
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 111In-platelet scintigraphy and two-dimensional echocardiography
Number of subjects: 40
Study: 31498898

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (specific details not provided)
Number of subjects: 521
Study: 28535410

Group type: EXPERIMENTAL
Intervention: Perampanel 1mg alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Perampanel 1mg with ketoconazole 400mg once daily for 10 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ketoconazole 400mg once daily for 10 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Simulations with larger doses of ketoconazole (e.g., 200mg every 6h for 30 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Simulations with a more potent inhibitor than ketoconazole (e.g., itraconazole)
Number of subjects: 26
Study: 25743541

Group type: EXPERIMENTAL
Intervention: Home game (HG)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Away game (AG)
Number of subjects: 297
Study: 24155139

Group type: EXPERIMENTAL
Intervention: Tocilizumab (intravenous dose based on body weight every 2 or 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tocilizumab
Number of subjects: 0
Study: 21700013

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional yogurt
Number of subjects: 60
Study: 19781318

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 16818571

Group type: EXPERIMENTAL
Intervention: Folate (5 mg daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (100 mg daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Folate and Vitamin B6 (combined)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 124
Study: 14738330

Group type: EXPERIMENTAL
Intervention: Items rated as 'very important' by speech-language pathologists regarding patient satisfaction with dysphagia services.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Items not rated as 'very important' by speech-language pathologists.
Number of subjects: 0
Study: 11140327

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba/Panax ginseng combination (60 mg GK501 and 100 mg G115)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 9007138

Group type: EXPERIMENTAL
Intervention: Paclitaxel 45 mg/m2 on days 1, 8, and 15 (level 1); 45 mg/m2 on days 1, 8, 15, 22, and 29 (level 2); 45 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43 (level 3); 55 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43 (level 4) with fixed dose radiotherapy (1.8 Gy/d for 6.5 weeks, total 59.4 Gy).
Number of subjects: 22
Study: 1319619

Group type: EXPERIMENTAL
Intervention: Logiparin (2,500 anti-Xa units once daily)
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: Logiparin (3,500 anti-Xa units once daily)
Number of subjects: 1290

Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 IU twice daily)
Number of subjects: 1290
Study: 6354937

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8
Study: 31843817

Group type: EXPERIMENTAL
Intervention: TTC (Teens Taking Charge)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iP2P-TTC (iPeer2Peer integrated with Teens Taking Charge)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TTC and iP2P with TTC
Number of subjects: 60
Study: 28709772

Group type: EXPERIMENTAL
Intervention: Psychoeducation sessions on diet and physical activity and regular participation in walking groups
Number of subjects: 326

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 326
Study: 26662964

Group type: EXPERIMENTAL
Intervention: Gla‐300
Number of subjects: 243

Group type: COMPARATOR
Intervention: Gla‐100
Number of subjects: 243
Study: 24423921

Group type: EXPERIMENTAL
Intervention: Axitinib 10 mg b.i.d. combined with FOLFIRI or FOLFOX
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Axitinib 10 mg b.i.d. for 7 days followed by 7 days interruption
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Axitinib 10 mg b.i.d. combined with chemotherapy
Number of subjects: 21
Study: 23135184

Group type: EXPERIMENTAL
Intervention: Micro-osteotomy assisted lower incisor decompensation (G1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional pre-surgical decomposition (G2)
Number of subjects: 22
Study: 20112006

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (Fampridine-SR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18031439

Group type: EXPERIMENTAL
Intervention: Nonsubmerged surgical technique (198 implants)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Submerged surgical technique (206 implants)
Number of subjects: 77
Study: 16048882

Group type: EXPERIMENTAL
Intervention: Public Access Defibrillation (PAD) Trial
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Social marketing techniques combined with behavior change models
Number of subjects: 61
Study: 12152111

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other ED therapies
Number of subjects: 0
Study: 10196013

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 66.7 microgram/kg, administered subcutaneously three times weekly for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7767692

Group type: EXPERIMENTAL
Intervention: Stress inoculation group participants
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Induction training group participants
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group participants
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Reminding older persons to use previously acquired training strategies
Number of subjects: 108

Group type: COMPARATOR
Intervention: No reminder effects
Number of subjects: 108
Study: 1291495

Group type: EXPERIMENTAL
Intervention: DL-carnitine (100 mg/kg/day in two divided doses orally for four days)
Number of subjects: 625

Group type: COMPARATOR
Intervention: No carnitine (control group)
Number of subjects: 625
Study: 6327139

Group type: EXPERIMENTAL
Intervention: Lentils
Number of subjects: 10

Group type: COMPARATOR
Intervention: Wholemeal bread and cottage cheese
Number of subjects: 10
Study: 30874755

Group type: EXPERIMENTAL
Intervention: ACC/AHA guidelines (2008-2018)
Number of subjects: 6330

Group type: EXPERIMENTAL
Intervention: ESC guidelines (2008-2018)
Number of subjects: 6330

Group type: COMPARATOR
Intervention: Comparison of current vs prior ACC/AHA guidelines
Number of subjects: 6330

Group type: COMPARATOR
Intervention: Comparison of current vs prior ESC guidelines
Number of subjects: 6330
Study: 29471300

Group type: EXPERIMENTAL
Intervention: Zevalin (Yttrium-90-Ibritumomab Tiuxetan) after 2 cycles of ESHAP chemotherapy
Number of subjects: 28
Study: 26901306

Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix (ADM) plus Mineralized Bone Allograft (AB)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Acellular Dermal Matrix (ADM) only
Number of subjects: 19
Study: 23344762

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Non-aspirin group (discontinued aspirin >7 days before surgery)
Number of subjects: 109
Study: 21798329

Group type: EXPERIMENTAL
Intervention: Active miswak
Number of subjects: 68

Group type: COMPARATOR
Intervention: Inactive miswak
Number of subjects: 68
Study: 19699454

Group type: EXPERIMENTAL
Intervention: 5mg of oxybutynin in sublingual form (Group O)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo in tablet form (Group P)
Number of subjects: 45
Study: 16394049

Group type: EXPERIMENTAL
Intervention: Women with a history of unplanned pregnancy
Number of subjects: 424

Group type: COMPARATOR
Intervention: Women without a history of unplanned pregnancy
Number of subjects: 424
Study: 15636224

Group type: EXPERIMENTAL
Intervention: apo E allele frequency in AMD patients (epsilon4 - 11.11%, epsilon2 - 7.77%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group allele frequency (epsilon4 - 13.6%, epsilon2 - 2.27%)
Number of subjects: 45
Study: 11676227

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg i.v.) administered 0.5 h before chemotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tropisetron (o.d. for 3 days)
Number of subjects: 30
Study: 9196082

Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 1397884

Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg orally or through a nasogastric tube, twice daily for 7 days
Number of subjects: 119
Study: 3892729

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg/d
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg/d
Number of subjects: 43
Study: 31202003

Group type: EXPERIMENTAL
Intervention: Internet and app-based gratitude intervention (5-week duration)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Wait list control group (WLG)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Internet and app-based gratitude intervention
Number of subjects: 260
Study: 29627596

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1200 mg/day of eicosapentaenoic acid and 600 mg/day of docosahexaenoic acid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 80
Study: 26814139

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Self-Monitoring Blood Glucose (SMBG)
Number of subjects: 106
Study: 25494622

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Social contact control intervention
Number of subjects: 62
Study: 22616181

Group type: EXPERIMENTAL
Intervention: Test preparation (Cyclosporin Soft Capsules)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference preparation (Cyclosporin Soft Capsules)
Number of subjects: 24
Study: 20047624

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg daily
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Combination therapy (atenolol and HCTZ)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Ambulatory Blood Pressure (ABP)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Office Blood Pressure (OBP)
Number of subjects: 418
Study: 18821658

Group type: EXPERIMENTAL
Intervention: adalimumab + MTX
Number of subjects: 148

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 148
Study: 16105427

Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 15
Study: 12060436

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg bid
Number of subjects: 228

Group type: COMPARATOR
Intervention: Oxybutynin 5 mg bid
Number of subjects: 228
Study: 10417452

Group type: EXPERIMENTAL
Intervention: Morphine 0.75 mg plus alfentanil 0.125 mg (Group MA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Morphine 1.5 mg alone (Group M)
Number of subjects: 77
Study: 7555166

Group type: EXPERIMENTAL
Intervention: Chemical and surgical pleurodesis
Number of subjects: 35

Group type: COMPARATOR
Intervention: Systemic corticosteroids for PCP treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cigarette smoking and aerosolized pentamidine treatment
Number of subjects: 35
Study: 2107519

Group type: EXPERIMENTAL
Intervention: Concurrent administration of Haemophilus influenzae type b conjugate vaccine with measles-mumps-rubella vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent administration of Haemophilus influenzae type b conjugate vaccine with diphtheria-tetanus-pertussis and oral poliovirus vaccines
Number of subjects: 0
Study: 424753

Group type: EXPERIMENTAL
Intervention: Fentanyl (intravenous administration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 40
Study: 31605793

Group type: EXPERIMENTAL
Intervention: NTX-010
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NTX-010 with detectable virus at days 7 and 14
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NTX-010 without detectable virus at days 7 and 14
Number of subjects: 50
Study: 30814669

Group type: COMPARATOR
Intervention: SELF group (standardised home self-training with a written training guide)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: REHAB group (training with an occupational therapist)
Number of subjects: 42
Study: 28718346

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 4279

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 4279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4279

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (both doses)
Number of subjects: 4279
Study: 26522499

Group type: EXPERIMENTAL
Intervention: Music therapy plus Pulmonary Rehabilitation (PR)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation alone
Number of subjects: 98
Study: 23528840

Group type: EXPERIMENTAL
Intervention: The 11+ injury prevention program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 21370402

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by tumor resection
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Solely radiochemotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Chemotherapy and tumor resection
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Incomplete tumor resection with postoperative radiochemotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall group (all treatments)
Number of subjects: 63
Study: 19135570

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg given 4 hours before D&E (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Doxycycline taken the night prior to D&E with dinner (Group 2)
Number of subjects: 40
Study: 17970536

Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water (BMW-1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water (BMW-2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-mineral water (LMW)
Number of subjects: 18
Study: 15733356

Group type: EXPERIMENTAL
Intervention: Parental education intervention (TV program, slides, brochure)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 11446582

Group type: EXPERIMENTAL
Intervention: Biofeedback training designed to increase right frontal alpha relative to left frontal alpha (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Biofeedback training designed to decrease right frontal alpha relative to left frontal alpha (n = 9)
Number of subjects: 18
Study: 9611023

Group type: EXPERIMENTAL
Intervention: Postoperative closed suction drainage using a single large Hemovac device for 2-5 days
Number of subjects: 108

Group type: COMPARATOR
Intervention: No drainage device (control group)
Number of subjects: 108
Study: 7802251

Group type: EXPERIMENTAL
Intervention: Clonidine 300 micrograms
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40